{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T10:49:07Z","timestamp":1784630947301,"version":"3.55.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2005,7]]},"DOI":"10.1124\/jpet.105.083923","type":"journal-article","created":{"date-parts":[[2005,6,17]],"date-time":"2005-06-17T02:07:56Z","timestamp":1118974076000},"page":"282-292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":116,"title":["Anxiolytic Effects of Maxipost (BMS-204352) and Retigabine via Activation of Neuronal Kv7 Channels"],"prefix":"10.1016","volume":"314","author":[{"given":"M.P.G.","family":"Korsgaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.P.","family":"Hartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.D.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.K.","family":"Ahring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Str\u00f8b\u00e6k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.R.","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.105.083923_bib1","doi-asserted-by":"crossref","unstructured":"Ahring PK, Str\u00f8b\u00e6k D, Christophersen P, Olesen SP, and Johansen TE (1997) Stable expression of the human large-conductance Ca2+-activated K+ channel alpha- and beta-subunits in HEK293 cells. FEBS Lett 415: 67-70.","DOI":"10.1016\/S0014-5793(97)01096-X"},{"key":"10.1124\/jpet.105.083923_bib2","doi-asserted-by":"crossref","unstructured":"Anand A and Shekhar A (2003) Brain imaging studies in mood and anxiety disorders: special emphasis on the amygdala. Ann NY Acad Sci 985: 370-388.","DOI":"10.1111\/j.1749-6632.2003.tb07095.x"},{"key":"10.1124\/jpet.105.083923_bib3","doi-asserted-by":"crossref","unstructured":"Biervert C, Schroeder BC, Kubisch C, Berkovic SF, Propping P, Jentsch TJ, and Steinlein OK (1998) A potassium channel mutation in neonatal human epilepsy. Science (Wash DC) 279: 403-406.","DOI":"10.1126\/science.279.5349.403"},{"key":"10.1124\/jpet.105.083923_bib4","doi-asserted-by":"crossref","unstructured":"Broekkamp CL, Rijk HW, Joly-Gelouin D, and Lloyd KL (1986) Major tranquillizers can be distinguished from minor tranquillizers on the basis of effects on marble burying and swim-induced grooming in mice. Eur J Pharmacol 126: 223-229.","DOI":"10.1016\/0014-2999(86)90051-8"},{"key":"10.1124\/jpet.105.083923_bib5","doi-asserted-by":"crossref","unstructured":"Brown DA and Adams PR (1980) Muscarinic suppression of a novel voltage-sensitive K+ current in a vertebrate neurone. Nature (Lond) 283: 673-676.","DOI":"10.1038\/283673a0"},{"key":"10.1124\/jpet.105.083923_bib6","doi-asserted-by":"crossref","unstructured":"Davis M (1992) The role of the amygdala in fear and anxiety. Annu Rev Neurosci 15: 353-375.","DOI":"10.1146\/annurev.ne.15.030192.002033"},{"key":"10.1124\/jpet.105.083923_bib7","unstructured":"Dieter H-R, Engel J, Kutscher B, Polymeropoulos E, Szelenyi S, and Nickel B (1996) inventors, Asta Medica AG, assignee. 1,2,4-Triaminobenzene derivatives and process for their preparation. Patent GR3019653T. 1996 Jul 31."},{"key":"10.1124\/jpet.105.083923_bib8","doi-asserted-by":"crossref","unstructured":"Dunnett SB, Rogers DC, and Jones GH (1989) Effects of nucleus basalis magnocellularis lesions in rats on delayed matching and non-matching to position tasks. Eur J Neurosci 1: 395-406.","DOI":"10.1111\/j.1460-9568.1989.tb00804.x"},{"key":"10.1124\/jpet.105.083923_bib9","doi-asserted-by":"crossref","unstructured":"Dupuis DS, Schr\u00f8der RL, Jespersen T, Christensen JK, Christophersen P, Jensen BS, and Olesen SP (2002) Activation of KCNQ5 channels stably expressed in HEK293 cells by BMS-204352. Eur J Pharmacol 437: 129-137.","DOI":"10.1016\/S0014-2999(02)01287-6"},{"key":"10.1124\/jpet.105.083923_bib10","unstructured":"Earl RA, Myers MJ, and Nickolson VJ (1989) inventors, Du Pont Merck Pharma, assignee. Alpha, alpha-disubstituted aromatics and heteroaromatics as cognition enhancers. Patent 311010A2. 1989 December 4."},{"key":"10.1124\/jpet.105.083923_bib11","doi-asserted-by":"crossref","unstructured":"Earl RA, Zaczek R, Teleha CA, Fisher BN, Maciag CM, Marynowski ME, Logue AR, Tam SW, Tinker WJ, Huang SM, and Chorvat RJ (1998) 2-Fluoro-4-pyridinylmethyl analogues of linopirdine as orally active acetylcholine release-enhancing agents with good efficacy and duration of action. J Med Chem 41: 4615-4622.","DOI":"10.1021\/jm9803424"},{"key":"10.1124\/jpet.105.083923_bib12","doi-asserted-by":"crossref","unstructured":"Ferron GM, Paul J, Fruncillo R, Richards L, Knebel N, Getsy J, and Troy S (2002) Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers. J Clin Pharmacol 42: 175-182.","DOI":"10.1177\/00912700222011210"},{"key":"10.1124\/jpet.105.083923_bib13","doi-asserted-by":"crossref","unstructured":"Green S (1991) Benzodiazepines, putative anxiolytics and animal models of anxiety. Trends Neurosci 14: 101-104.","DOI":"10.1016\/0166-2236(91)90070-B"},{"key":"10.1124\/jpet.105.083923_bib14","doi-asserted-by":"crossref","unstructured":"Gribkoff VK (2003) The therapeutic potential of neuronal KCNQ channel modulators. Expert Opin Ther Targets 7: 737-748.","DOI":"10.1517\/eott.7.6.737.22569"},{"key":"10.1124\/jpet.105.083923_bib15","doi-asserted-by":"crossref","unstructured":"Gribkoff VK, Starrett JE Jr, Dworetzky SI, Hewawasam P, Boissard CG, Cook DA, Frantz SW, Heman K, Hibbard JR, Huston K, et al. (2001) Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels. Nat Med 7: 471-477.","DOI":"10.1038\/86546"},{"key":"10.1124\/jpet.105.083923_bib16","doi-asserted-by":"crossref","unstructured":"Grunnet M, Jespersen T, Rasmussen HB, Ljungstr\u00f8m T, J\u00f8rgensen NK, Olesen SP, and Kl\u00e6rke DA (2002) KCNE4 is an inhibitory subunit to the KCNQ1 channel. J Physiol 542: 119-130.","DOI":"10.1113\/jphysiol.2002.017301"},{"key":"10.1124\/jpet.105.083923_bib17","unstructured":"Ilyin VI, Carlin KP, Hodges DD, Robledo S, and Woodward RM (2002) Flupirtine-a positive modulator of heteromeric KCNQ2\/3 channels (Abstract). Soc Neurosci Abstr 758.10."},{"key":"10.1124\/jpet.105.083923_bib18","unstructured":"Irwin S (1969) Pre-clinical drug evaluation and method development. Psychopharmacol Bull 5: 27-28."},{"key":"10.1124\/jpet.105.083923_bib19","doi-asserted-by":"crossref","unstructured":"Jensen ML, Timmermann DB, Johansen TH, Schousboe A, Varming T, and Ahring PK (2002) The beta subunit determines the ion selectivity of the GABAA receptor. J Biol Chem 277: 41438-41447.","DOI":"10.1074\/jbc.M205645200"},{"key":"10.1124\/jpet.105.083923_bib20","doi-asserted-by":"crossref","unstructured":"Kharkovets T, Hardelin JP, Safieddine S, Schweizer M, El Amraoui A, Petit C, and Jentsch TJ (2000) KCNQ4, a K+ channel mutated in a form of dominant deafness, is expressed in the inner ear and the central auditory pathway. Proc Natl Acad Sci USA 97: 4333-4338.","DOI":"10.1073\/pnas.97.8.4333"},{"key":"10.1124\/jpet.105.083923_bib21","unstructured":"Korsgaard MPG, Herrik KF, Brown WD, Christophersen P, and Str\u00f8b\u00e6k D (2003) Flupirtine activates KCNQ channels (Abstract). Biophys J S84: 547a."},{"key":"10.1124\/jpet.105.083923_bib22","unstructured":"Lattal KA (1991) Scheduling positive reinforcers, in Experimental Analysis of Behaviour Part 1. Elsevier Science, B.V., Amsterdam."},{"key":"10.1124\/jpet.105.083923_bib23","doi-asserted-by":"crossref","unstructured":"Main MJ, Cryan JE, Dupere JR, Cox B, Clare JJ, and Burbidge SA (2000) Modulation of KCNQ2\/3 potassium channels by the novel anticonvulsant retigabine. Mol Pharmacol 58: 253-262.","DOI":"10.1124\/mol.58.2.253"},{"key":"10.1124\/jpet.105.083923_bib24","doi-asserted-by":"crossref","unstructured":"Meis S and Pape HC (1997) Properties of a Ca2+-activated K+ conductance in acutely isolated pyramidal-like neurons from the rat basolateral amygdaloid complex. J Neurophysiol 78: 1256-1262.","DOI":"10.1152\/jn.1997.78.3.1256"},{"key":"10.1124\/jpet.105.083923_bib25","doi-asserted-by":"crossref","unstructured":"Pare D and Collins DR (2000) Neuronal correlates of fear in the lateral amygdala: multiple extracellular recordings in conscious cats. J Neurosci 20: 2701-2710.","DOI":"10.1523\/JNEUROSCI.20-07-02701.2000"},{"key":"10.1124\/jpet.105.083923_bib26","doi-asserted-by":"crossref","unstructured":"Passmore GM, Selyanko AA, Mistry M, Al Qatari M, Marsh SJ, Matthews EA, Dickenson AH, Brown TA, Burbidge SA, Main M, and Brown DA (2003) KCNQ\/M currents in sensory neurons: significance for pain therapy. J Neurosci 23: 7227-7236.","DOI":"10.1523\/JNEUROSCI.23-18-07227.2003"},{"key":"10.1124\/jpet.105.083923_bib27","unstructured":"Pendri YR, Martinez EJ, Thottathil JK, and Hewawasam P (1997) inventors, Squibb Bristol Myers Co., assignee. Preparation of 3-fluoro oxindole derivatives. U.S. patent WO9816222. 1998 Feb 24."},{"key":"10.1124\/jpet.105.083923_bib28","doi-asserted-by":"crossref","unstructured":"Racine RJ (1972) Modification of seizure activity by electrical stimulation. I. After-discharge threshold. Electroencephalogr Clin Neurophysiol 32: 269-279.","DOI":"10.1016\/0013-4694(72)90176-9"},{"key":"10.1124\/jpet.105.083923_bib29","doi-asserted-by":"crossref","unstructured":"Rauch SL, Shin LM, and Wright CI (2003) Neuroimaging studies of amygdala function in anxiety disorders. Ann NY Acad Sci 985: 389-410.","DOI":"10.1111\/j.1749-6632.2003.tb07096.x"},{"key":"10.1124\/jpet.105.083923_bib30","doi-asserted-by":"crossref","unstructured":"Robbins J (2001) KCNQ potassium channels: physiology, pathophysiology and pharmacology. Pharmacol Ther 90: 1-19.","DOI":"10.1016\/S0163-7258(01)00116-4"},{"key":"10.1124\/jpet.105.083923_bib31","doi-asserted-by":"crossref","unstructured":"Rosen JB and Schulkin J (1998) From normal fear to pathological anxiety. Psychol Rev 105: 325-350.","DOI":"10.1037\/\/0033-295X.105.2.325"},{"key":"10.1124\/jpet.105.083923_bib32","doi-asserted-by":"crossref","unstructured":"Rostock A, Tober C, Rundfeldt C, Bartsch R, Engel J, Polymeropoulos EE, Kutscher B, Loscher W, Honack D, White HS, and Wolf HH (1996) D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures 9. Epilepsy Res 23: 211-223.","DOI":"10.1016\/0920-1211(95)00101-8"},{"key":"10.1124\/jpet.105.083923_bib33","doi-asserted-by":"crossref","unstructured":"Rundfeldt C and Netzer R (2000) Investigations into the mechanism of action of the new anticonvulsant retigabine. Interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels. Arzneimittelforschung 50: 1063-1070.","DOI":"10.1055\/s-0031-1300346"},{"key":"10.1124\/jpet.105.083923_bib34","doi-asserted-by":"crossref","unstructured":"Saganich MJ, Machado E, and Rudy B (2001) Differential expression of genes encoding subthreshold-operating voltage-gated K+ channels in brain. J Neurosci 21: 4609-4624.","DOI":"10.1523\/JNEUROSCI.21-13-04609.2001"},{"key":"10.1124\/jpet.105.083923_bib35","doi-asserted-by":"crossref","unstructured":"Schr\u00f8der RL, Jespersen T, Christophersen P, Str\u00f8b\u00e6k D, Jensen BS, and Olesen SP (2001) KCNQ4 channel activation by BMS-204352 and retigabine. Neuropharmacology 40: 888-898.","DOI":"10.1016\/S0028-3908(01)00029-6"},{"key":"10.1124\/jpet.105.083923_bib36","doi-asserted-by":"crossref","unstructured":"Schr\u00f8der RL, Str\u00f8b\u00e6k D, Olesen SP, and Christophersen P (2003) Voltage-independent KCNQ4 currents induced by (+\/-)BMS-204352. Pflugers Arch 446: 607-616.","DOI":"10.1007\/s00424-003-1116-x"},{"key":"10.1124\/jpet.105.083923_bib37","doi-asserted-by":"crossref","unstructured":"Schroeder BC, Hechenberger M, Weinreich F, Kubisch C, and Jentsch TJ (2000a) KCNQ5, a novel potassium channel broadly expressed in brain, mediates M-type currents. J Biol Chem 275: 24089-24095.","DOI":"10.1074\/jbc.M003245200"},{"key":"10.1124\/jpet.105.083923_bib38","doi-asserted-by":"crossref","unstructured":"Schroeder BC, Waldegger S, Fehr S, Bleich M, Warth R, Greger R, and Jentsch TJ (2000b) A constitutively open potassium channel formed by KCNQ1 and KCNE3. Nature (Lond) 403: 196-199.","DOI":"10.1038\/35003200"},{"key":"10.1124\/jpet.105.083923_bib39","doi-asserted-by":"crossref","unstructured":"Shepherd JK, Grewal SS, Fletcher A, Bill DJ, and Dourish CT (1994) Behavioural and pharmacological characterisation of the elevated \u201czero-maze\u201d as an animal model of anxiety. Psychopharmacology (Berl) 116: 56-64.","DOI":"10.1007\/BF02244871"},{"key":"10.1124\/jpet.105.083923_bib40","doi-asserted-by":"crossref","unstructured":"Singh NA, Charlier C, Stauffer D, DuPont BR, Leach RJ, Melis R, Ronen GM, Bjerre I, Quattlebaum T, Murphy JV, et al. (1998) A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat Genet 18: 25-29.","DOI":"10.1038\/ng0198-25"},{"key":"10.1124\/jpet.105.083923_bib41","doi-asserted-by":"crossref","unstructured":"S\u00f8gaard R, Ljungstr\u00f8m T, Pedersen KA, Olesen SP, and Jensen BS (2001) KCNQ4 channels expressed in mammalian cells: functional characteristics and pharmacology 2. Am J Physiol 280: C859-C866.","DOI":"10.1152\/ajpcell.2001.280.4.C859"},{"key":"10.1124\/jpet.105.083923_bib42","doi-asserted-by":"crossref","unstructured":"Stanhope KJ and Dourish CT (1996) Effects of 5-HT1A receptor agonists, partial agonists and a silent antagonist on the performance of the conditioned emotional response test in the rat. Psychopharmacology (Berl) 128: 293-303.","DOI":"10.1007\/s002130050137"},{"key":"10.1124\/jpet.105.083923_bib43","doi-asserted-by":"crossref","unstructured":"Steriade M and McCarley RW (1990) Brainstem Control of Wakefulness and Sleep. Plenum Publishing Corporation, New York.","DOI":"10.1007\/978-1-4757-4669-3"},{"key":"10.1124\/jpet.105.083923_bib44","doi-asserted-by":"crossref","unstructured":"Str\u00f8b\u00e6k D, J\u00f8rgensen TD, Christophersen P, Ahring PK, and Olesen SP (2000) Pharmacological characterization of small-conductance Ca(2+)-activated K(+) channels stably expressed in HEK 293 cells. Br J Pharmacol 129: 991-999.","DOI":"10.1038\/sj.bjp.0703120"},{"key":"10.1124\/jpet.105.083923_bib45","doi-asserted-by":"crossref","unstructured":"Sullivan GM, Apergis J, Gorman JM, and LeDoux JE (2003) Rodent doxapram model of panic: behavioral effects and c-Fos immunoreactivity in the amygdala. Biol Psychiatry 53: 863-870.","DOI":"10.1016\/S0006-3223(02)01733-X"},{"key":"10.1124\/jpet.105.083923_bib46","doi-asserted-by":"crossref","unstructured":"Tatulian L, Delmas P, Abogadie FC, and Brown DA (2001) Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine. J Neurosci 21: 5535-5545.","DOI":"10.1523\/JNEUROSCI.21-15-05535.2001"},{"key":"10.1124\/jpet.105.083923_bib47","doi-asserted-by":"crossref","unstructured":"Wang HS, Brown BS, McKinnon D, and Cohen IS (2000) Molecular basis for differential sensitivity of KCNQ and IKs channels to the cognitive enhancer XE991. Mol Pharmacol 57: 1218-1223.","DOI":"10.1016\/S0026-895X(24)23232-6"},{"key":"10.1124\/jpet.105.083923_bib48","doi-asserted-by":"crossref","unstructured":"Womble MD and Moises HC (1992) Muscarinic inhibition of M-current and a potassium leak conductance in neurones of the rat basolateral amygdala. J Physiol 457: 93-114.","DOI":"10.1113\/jphysiol.1992.sp019366"},{"key":"10.1124\/jpet.105.083923_bib49","doi-asserted-by":"crossref","unstructured":"Yang WP, Levesque PC, Little WA, Conder ML, Ramakrishnan P, Neubauer MG, and Blanar MA (1998) Functional expression of two KvLQT1-related potassium channels responsible for an inherited idiopathic epilepsy. J Biol Chem 273: 19419-19423.","DOI":"10.1074\/jbc.273.31.19419"},{"key":"10.1124\/jpet.105.083923_bib50","doi-asserted-by":"crossref","unstructured":"Yang WP, Levesque PC, Little WA, Conder ML, Shalaby FY, and Blanar MA (1997) KvLQT1, a voltage-gated potassium channel responsible for human cardiac arrhythmias. Proc Natl Acad Sci USA 94: 4017-4021.","DOI":"10.1073\/pnas.94.8.4017"},{"key":"10.1124\/jpet.105.083923_bib51","doi-asserted-by":"crossref","unstructured":"Zaczek R, Chorvat RJ, Saye JA, Pierdomenico ME, Maciag CM, Logue AR, Fisher BN, Rominger DH, and Earl RA (1998) Two new potent neurotransmitter release enhancers, 10,10-bis(4-pyridinylmethyl)-9(10 H)-anthracenone and 10,10-bis(2-fluoro-4-pyridinylmethyl)-9(10 H)-anthracenone: comparison to linopirdine. J Pharmacol Exp Ther 285: 724-730.","DOI":"10.1016\/S0022-3565(24)37471-3"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652432083X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652432083X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.105.083923","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T21:29:42Z","timestamp":1740000582000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235652432083X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["S002235652432083X"],"URL":"https:\/\/doi.org\/10.1124\/jpet.105.083923","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2005,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anxiolytic Effects of Maxipost (BMS-204352) and Retigabine via Activation of Neuronal Kv7 Channels","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.105.083923","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2005 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}